David Mehalick's Insider Trades & SAST Disclosures

David Mehalick's most recent trade in Coeptis Therapeutics Holdings Inc was a trade of 148,875 Common stock done at an average price of $7.1 . Disclosure was reported to the exchange on Feb. 11, 2026.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Coeptis Therapeutics Holdings Inc
David Mehalick Director, CEO and President, Ten Percent Owner Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.05 per share. 11 Feb 2026 148,875 330,192 - 7.1 1,049,569 Common stock
Coeptis Therapeutics Holdings Inc
David Mehalick Director, CEO and President, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Feb 2026 51,250 330,192 - 0 Common Stock
Coeptis Therapeutics Holdings Inc
David Mehalick Director, CEO and President, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Mar 2025 28,875 200,125 - - Non-Qualified Stock Options (right to buy)
Coeptis Therapeutics Holdings Inc
David Mehalick Director, CEO and President, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 0.66 per share. 05 Jan 2024 14,004 2,782,615 - 0.7 9,243 Common Stock
Coeptis Therapeutics Holdings Inc
Mehalick David Director, CEO and President, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 0.67 per share. 05 Jan 2024 6,000 2,768,611 - 0.7 4,020 Common Stock
Coeptis Therapeutics Holdings Inc
David Mehalick Director, CEO and President, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 0.69 per share. 05 Jan 2024 5,050 2,762,611 - 0.7 3,485 Common Stock
Coeptis Therapeutics Holdings Inc
David Mehalick Director, CEO and President, Ten Percent Owner Gift of securities by or to the insider at price $ 0.00 per share. 07 Dec 2023 700,000 2,757,561 - 0 Common Stock
Coeptis Therapeutics Holdings Inc
David Mehalick Director, CEO and President, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2023 375,000 375,000 - - Non-qualified Stock Options (right to buy)
Coeptis Therapeutics Holdings Inc
David Mehalick Director, CEO and President, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2023 250,000 250,000 - - Incentive Stock Options (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades